Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

NCT00933231 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00933231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00933231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
August 17, 2009
Completion date
April 3, 2018
Enrollment
281 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation